Author: Steve Kopczak

LitAlert ~~ GeneLit.com

    • DNA Repair Deficiency as Circulating Biomarker in Prostate Cancer.
    • Roviello G, Generali D, Gatti M, Riboli B, Paganini L, Nesi G, Catalano M.
    • Front Oncol. 2023 Jan 12;12:1115241. doi: 10.3389/fonc.2023.1115241.

    • Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches.
    • Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, Grünwald V.
    • Cancers (Basel). 2023 Jan 11;15(2):461. doi: 10.3390/cancers15020461.

    • Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the results from the Advanced Prostate Cancer Consensus Conference.
    • Fujita K, Suzuki H, Hinata N, Miura Y, Edamura K, Tabata KI, Arai G, Matsubara N, Yasumizu Y, Kosaka T, Oya M, Sugimoto M.
    • Transl Androl Urol. 2022 Dec;11(12):1771-1785. doi: 10.21037/tau-22-396.

    Related:

    •• Commentary:

    Assessment of real-world application of advanced prostate cancer management in Japan.

    • LitAlert ~~ GeneLit.com

    • The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study.
    • Chu DT, Vu Ngoc Suong M, Vu Thi H, Vu TD, Nguyen MH, Singh V.
    • Expert Rev Mol Diagn. 2023 Jan 12. doi: 10.1080/14737159.2023.2168190. Epub ahead of print.
    • Review

    • Inherited mutations in Chinese patients with upper tract urothelial carcinoma.
    • Wu J, Jin S, Gu C, Wei Y, Zhu Y, Necchi A, Shariat SF, Pan J, Gan H, Dai B, Zhang H, Shi G, Zhu Y, Shen Y, Zhu Y, Ye D.
    • Cell Rep Med. 2022 Dec 23:100883. doi: 10.1016/j.xcrm.2022.100883. Epub ahead of print.

    • Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the results from the Advanced Prostate Cancer Consensus Conference.
    • Fujita K, Suzuki H, Hinata N, Miura Y, Edamura K, Tabata KI, Arai G, Matsubara N, Yasumizu Y, Kosaka T, Oya M, Sugimoto M.
    • Transl Androl Urol. 2022 Dec;11(12):1771-1785. doi: 10.21037/tau-22-396.

    Related:

    •• Commentary:

    Assessment of real-world application of advanced prostate cancer management in Japan.

    • LitAlert ~~ GeneLit.com

    • Learning about My Mother’s PALB2 Mutation was a Gift to Our Family.
    • Smith K.
    • FORCE. Blog. 2023 Jan 13.

    • The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study.
    • Chu DT, Vu Ngoc Suong M, Vu Thi H, Vu TD, Nguyen MH, Singh V.
    • Expert Rev Mol Diagn. 2023 Jan 12. doi: 10.1080/14737159.2023.2168190. Epub ahead of print.
    • Review

    • Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches.
    • Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, Grünwald V.
    • Cancers (Basel). 2023 Jan 11;15(2):461. doi: 10.3390/cancers15020461.

    • The research landscape of the quality of life or psychological impact on gynecological cancer patients: a bibliometric analysis.
    • Zhao J, Kong Y, Xiang Y, Yang J.
    • Front Oncol. 2023 Jan 10;12:1115852. doi: 10.3389/fonc.2023.1115852.

    • Inherited mutations in Chinese patients with upper tract urothelial carcinoma.
    • Wu J, Jin S, Gu C, Wei Y, Zhu Y, Necchi A, Shariat SF, Pan J, Gan H, Dai B, Zhang H, Shi G, Zhu Y, Shen Y, Zhu Y, Ye D.
    • Cell Rep Med. 2022 Dec 23:100883. doi: 10.1016/j.xcrm.2022.100883. Epub ahead of print.

    • Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the results from the Advanced Prostate Cancer Consensus Conference.
    • Fujita K, Suzuki H, Hinata N, Miura Y, Edamura K, Tabata KI, Arai G, Matsubara N, Yasumizu Y, Kosaka T, Oya M, Sugimoto M.
    • Transl Androl Urol. 2022 Dec;11(12):1771-1785. doi: 10.21037/tau-22-396.

    Related:

    •• Commentary:

    Assessment of real-world application of advanced prostate cancer management in Japan.

    • LitAlert ~~ GeneLit.com

    • Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
    • Bellier C, Gladieff L, Le Du F, Berton D, Bonnard C, Suau D, Richard AC, Brenner O, Lahouegue A, Freyer G, Floquet A, Frank S, Kfoury M.
    • Drugs Real World Outcomes. 2023 Jan 11. doi: 10.1007/s40801-022-00349-9. Epub ahead of print.

    • A Glance at Molecular Advances in Cancer Genetics: A Baffling Puzzle Still to Be Solved.
    • Ghiorzo P, Bruno W.
    • Int J Mol Sci. 2023 Jan 11;24(2):1394. doi: 10.3390/ijms24021394.

    • Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery.
    • Cortina CS.
    • JAMA Surg. 2023 Jan 11. doi: 10.1001/jamasurg.2022.5447. Epub ahead of print.
    • Commentary

    • Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom [Clinically relevant molecular pathological diagnostics in breast cancer].
    • Rodepeter FR, Teply-Szymanski J, Romey M, Grass A, Erber R, Lebeau A, Mack EKM, Tarawneh TS, Gremke N, Boekhoff J, Wündisch T, Wagner U, Jank P, Denkert C.
    • Pathologie (Heidelb). 2023 Jan 11. German. doi: 10.1007/s00292-022-01175-0. Epub ahead of print.
    • Review. [Article in German]

    • Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC.
    • Dorff TB.
    • OncLive. OncLive TV. 2023 Jan 10.

    • LitAlert ~~ GeneLit.com

    • Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study.
    • Zhang C, Zhu D, Qu Y, Shi M, Ma J, Peng Y, Zhu B, Tao H, Ma T, Hou T.
    • J Med Genet. 2023 Jan 10:jmg-2022-108816. doi: 10.1136/jmg-2022-108816. Epub ahead of print.

    • Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.
    • Pederson HJ, Batur P.
    • Menopause. 2023 Jan 10. doi: 10.1097/GME.0000000000002136. Epub ahead of print.
    • Review

    • Development and Clinical Applications of an Enclosed Automated Targeted NGS Library Preparation System.
    • Shi C, Feng Y, Sun R, Chen J, Zhao Y, Wang Z, Xie S, Zhou J, Yang L, Cao X, Feng J, Zhang C, Wei B, Wang X, Chang Y, Zhao J, Wang Z, Zheng J, Liu J, Chantratita W, Xiong L, Zhang D, Chen C, Ma J.
    • Clin Chim Acta. 2023 Jan 7:117224. doi: 10.1016/j.cca.2023.117224. Epub ahead of print.

    • EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
    • Schmidt MK, Kelly JE, Brédart A, Cameron DA, de Boniface J, Easton DF, Offersen BV, Poulakaki F, Rubio IT, Sardanelli F, Schmutzler R, Spanic T, Weigelt B, Rutgers EJT.
    • Eur J Cancer. 2023 Jan 10. doi: 10.1016/j.ejca.2022.11.036. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
    • Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinier S, Guerra Alía EM, Polterauer S, Yoshida H, Vergote I, Colombo N, Hietanen S, Largillier R, Canzler U, Gratet A, Marmé F, Favier L, Pujade-Lauraine E, Ray-Coquard I.
    • Eur J Cancer. 2023 Jan 10. doi: 10.1016/j.ejca.2022.11.029. Epub ahead of print.

    Related:

    •• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 10.)

    • EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
    • Schmidt MK, Kelly JE, Brédart A, Cameron DA, de Boniface J, Easton DF, Offersen BV, Poulakaki F, Rubio IT, Sardanelli F, Schmutzler R, Spanic T, Weigelt B, Rutgers EJT.
    • Eur J Cancer. 2023 Jan 10. doi: 10.1016/j.ejca.2022.11.036. Epub ahead of print.

    • Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers.
    • Flaherty C, Dorff TB.
    • OncLive. 2023 Jan 10.

    • Ideaya to Launch PARG Inhibitor Trial in Homologous Recombination Repair-Deficient Cancers.
    • [No author given]
    • Precision Oncology News. 2023 Jan 9.

    • Targeting the DNA damage response for cancer therapy.
    • Curtin NJ.
    • Biochem Soc Trans. 2023 Jan 6:BST20220681. doi: 10.1042/BST20220681. Epub ahead of print.

    • Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer.
    • Wang XC, Zhou H, Jiang WJ, Jiang P, Sun YC, Ni WJ.
    • Front Genet. 2023 Jan 6;12:1065213. doi: 10.3389/fgene.2022.1065213.

    • Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    • Kim J, Jeong K, Jun H, Kim K, Bae JM, Song MG, Yi H, Park S, Woo GU, Lee DW, Kim TY, Lee KH, Im SA.
    • Hum Genomics. 2023 Jan 6;17(1):2. doi: 10.1186/s40246-022-00447-3.

    • Oncologic Safety of Nipple-Sparing Mastectomy for Breast Cancer in BRCA Gene Mutation Carriers: Outcomes at 70 Months Median Follow-Up.
    • Webster AJ, Shanno JN, Santa Cruz HS, Kelly BN, Garstka M, Henriquez A, Specht MC, Gadd MA, Verdial FC, Nguyen A, Oseni TO, Coopey SB, Smith BL.
    • Ann Surg Oncol. 2023 Jan 5. doi: 10.1245/s10434-022-13006-w. Epub ahead of print.

    • Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary.
    • Penn CA, Alvarez RD.
    • JCO Oncol Pract. 2023 Jan 5:OP2200461. doi: 10.1200/OP.22.00461. Epub ahead of print.

    • Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    • Guney Eskiler G, Ozman Z, Haciefendi A, Cansaran-Duman D.
    • Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan 4. doi: 10.1007/s00210-022-02375-4. Epub ahead of print.

    • Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    • Qi F, Xu Z, Zou Q.
    • Eur Urol. 2023 Jan 3:S0302-2838(22)02873-1. doi: 10.1016/j.eururo.2022.12.024. Epub ahead of print.
    • Letter

    Related:

    •• Original research:

    Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.

    •• Reply:

    Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.

    • Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
    • Vera R, Ibarrola-de Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, Macarulla T, Serrano-Piñol T, Mondéjar R, Madrigal-Rubiales B.
    • Rev Esp Patol. 2023 Jan-Mar;56(1):32-44. doi: 10.1016/j.patol.2022.06.004. Epub 2022 Aug 26.
    • Review

    • A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome.
    • Oki R, Urasaki T, Ueki A, Inamura K, Komai Y, Takahashi S, Yonese J, Yuasa T.
    • IJU Case Rep. 2022 Oct 28 [eCollection 2023 Jan];6(1):33-36. doi: 10.1002/iju5.12542.

    • Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin.
    • Miyazawa Y, Shimizu T, Sekine Y, Arai S, Ohtsu A, Fujizuka Y, Nomura M, Koike H, Matsui H, Suzuki K.
    • IJU Case Rep. 2022 Oct 9 [eCollection 2023 Jan];6(1):37-40. doi: 10.1002/iju5.12543.

    Related:

    •• Letter:

    Editorial Comment on "Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin".

    • Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
    • Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI.
    • J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25. Epub ahead of print.

    • Ideaya Biosciences Files IND With FDA for PARG Inhibitor.
    • [No author goven]
    • Precision Oncology News. 2022 Dec 12.

    • LitAlert ~~ GeneLit.com

    • Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    • Kim J, Jeong K, Jun H, Kim K, Bae JM, Song MG, Yi H, Park S, Woo GU, Lee DW, Kim TY, Lee KH, Im SA.
    • Hum Genomics. 2023 Jan 6;17(1):2. doi: 10.1186/s40246-022-00447-3.

    • Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    • Guney Eskiler G, Ozman Z, Haciefendi A, Cansaran-Duman D.
    • Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan 4. doi: 10.1007/s00210-022-02375-4. Epub ahead of print.